Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.
Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.
The first days at SXSW Health went deep on entrepreneurship and the marketing thereof.
The MM&M Transforming Healthcare Conference will be held May 1 in New York City.
The organization is now called Havas Health & You and continues to be led by Donna Murphy.
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.
WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking
This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
The Medical Advertising Hall of Fame recognized dozens of industry leaders and rising agency executives.
At the very least, pharma marketers need to make sure they know the difference between search engine marketing and search engine optimization.
Novo Nordisk appoints new CEO, and more people moves for you to know about
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.
Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.
The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.
A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.
Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Publicis Health formalizes new name, promotes 3 execs
- Digital IDs become focus as drugmakers seek to track doctors' behavior online